Pharmacokinetically Guided Administration of Chemotherapeutic Agents

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Clinical Pharmacokinetics

• Publication date

  2000-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/00003088-200039050-00004PMID 11108434
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve

  2009cited by this paper
• A pharmacogically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer

  2009cited by this paper
• Overview of recent topics in clinical pharmacology of anticancer agents

  2009cited by this paper
• Clinical pharmacodynamic studies of high-dose methotrexate in acute lymphocytic leukemia.

  2009cited by this paper
• The use of the Calvert formula to determine the optimal carboplatin dosage

  2005cited by this paper
• Limited-sampling models for anticancer agents

  2005cited by this paper
• A limited sampling method for estimation of the carboplatin area under the curve

  2004cited by this paper
• Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose

  2004cited by this paper
• Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation

  2004cited by this paper
• Approaches to optimal dosing of hexamethylene bisacetamide

  2004cited by this paper
• Phase II study of 4′-iodo-4′-deoxydoxorubicin in non-resectable non-small-cell lung cancer

  2004cited by this paper
• Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination

  2004cited by this paper
• Renal handling of carboplatin

  2004cited by this paper
• Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer

  2004cited by this paper
• Clinical pharmacodynamics of continuous-infusion etoposide

  2004cited by this paper
• Pharmacokinetics of continuous-infusion amsacrine and teniposide for the treatment of relapsed childhood acute nonlymphocytic leukemia

  2004cited by this paper
• A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement

  2004cited by this paper
• Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin

  2004cited by this paper
• High-dose methotrexate: Preliminary evaluation of a pharmacokinetic approach

  2004cited by this paper
• Dose intensity of carboplatin in combination with cyclophosphamide or ifosfamide

  2004cited by this paper
• Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer

  2004cited by this paper
• Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients

  2004cited by this paper
• Validation of techniques for the prediction of carboplatin exposure: Application of Bayesian methods

  2000cited by this paper
• Individual 5FU-dose adaptation schedule using bimonthly pharmacokinetically modulated LV5FU2 regimen: a feasibility study in patients with advanced colorectal cancer.

  1999cited by this paper
• A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel

  1999cited by this paper
• Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer

  1999cited by this paper
• Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels.

  1999cited by this paper
• A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen

  1999cited by this paper
• Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer.

  1999cited by this paper
• A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. European Lung Cancer Working Party.

  1999cited by this paper
• Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae

  1998cited by this paper
• Improvement of the Cockcroft-Gault equation for predicting glomerular filtration in cancer patients.

  1998cited by this paper
• Estimation of the area under the concentration-versus-time curve of carboplatin following irinotecan using a limited sampling model

  1998cited by this paper
• Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

  1998cited by this paper
• Pharmacokinetics of anticancer agents in patients with impaired liver function.

  1998cited by this paper
• Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients.

  1998cited by this paper
• Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group.

  1998cited by this paper
• A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children.

  1998cited by this paper
• A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte‐colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma

  1998cited by this paper
• Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas.

  1998cited by this paper
• Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia.

  1998cited by this paper
• A clinician's guide to chemotherapy pharmacokinetics and pharmacodynamics

  1998cited by this paper
• Practical Treatment Guide for Dose Individualisation in Cancer Chemotherapy

  1998cited by this paper
• Combination chemotherapy studies with gemcitabine.

  1997cited by this paper
• A Bayesian dosing method for carboplatin given by continuous infusion for 120 h

  1997cited by this paper
• A sequential Bayesian algorithm for dose individualisation of carboplatin

  1997cited by this paper
• A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel.

  1997cited by this paper
• A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.

  1997cited by this paper
• Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing.

  1997cited by this paper
• A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel.

  1997cited by this paper
• Re: prediction of carboplatin clearance from standard morphological and biological patient characteristics.

  1997cited by this paper
• COMMENT ON : PREDICTION OF CARBOPLATIN CLEARANCE FROM STANDARD MORPHOLOGICAL AND BIOLOGICAL PATIENT CHARACTERISTICS. AUTHORS' REPLY

  1997cited by this paper
• Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial.

  1997cited by this paper
• Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.

  1997cited by this paper
• Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.

  1997cited by this paper
• Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.

  1997cited by this paper
• Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.

  1997cited by this paper
• Clinical Pharmacokinetics and Dose Optimisation of Carboplatin

  1997cited by this paper
• Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study.

  1997cited by this paper
• Relationship between 5‐fluorouracil (5‐FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5‐FU

  1996cited by this paper
• Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer.

  1996cited by this paper
• Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.

  1996cited by this paper
• Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancer.

  1996cited by this paper
• The Use of Population Pharmacokinetics in Drug Development

  1996cited by this paper
• A comparison of methods for limited-sampling strategy design using data from a phase I trial of the anthrapyrazole DuP-941

  1996cited by this paper
• Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure

  1996cited by this paper
• Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.

  1996cited by this paper
• Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.

  1996cited by this paper
• Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients

  1996cited by this paper
• Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.

  1996cited by this paper
• Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer.

  1996cited by this paper
• Association of busulfan area under the curve with veno-occlusive disease following BMT.

  1996cited by this paper
• Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel.

  1996cited by this paper
• Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.

  1996cited by this paper
• Pharmacokinetic modelling--a prelude to therapeutic drug monitoring for all cancer patients?

  1995cited by this paper
• Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions.

  1995cited by this paper
• Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.

  1995cited by this paper
• 926 Pharmacokinetics (PK), clinical pharmacodynamics (PD) and safety of chronic oral topotecan (T), in a phase I study

  1995cited by this paper
• Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin

  1995cited by this paper
• Prediction of carboplatin clearance from standard morphological and biological patient characteristics.

  1995cited by this paper
• A Limited Sampling Model with Bayesian Estimation to Determine Inulin Pharmacokinetics Using the Population Data Modelling Program P-PHARM

  1995cited by this paper
• Clinical pharmacological evaluation of CPT-11 and cisplatin (CDDP) in patients with small cell lung cancer (SCLC)

  1995cited by this paper
• Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks

  1995cited by this paper
• Continuous carboplatin infusion during 6 weeks' radiotherapy in locally inoperable non-small-cell lung cancer: a phase I and pharmacokinetic study.

  1995cited by this paper
• A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer.

  1995cited by this paper
• Pharmacokinetics and pharmacodynamics of 21‐day continuous oral etoposide in pediatric patients with solid tumors

  1995cited by this paper
• Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation

  1995cited by this paper
• Pharmacokinetics of paclitaxel and carboplatin in combination.

  1995cited by this paper
• Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.

  1995cited by this paper
• Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function.

  1995cited by this paper
• Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer.

  1995cited by this paper
• Dose optimisation of carboplatin in adults.

  1994cited by this paper
• Limited sampling models for topotecan pharmacokinetics.

  1994cited by this paper
• Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.

  1994cited by this paper
• Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.

  1994cited by this paper
• Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors.

  1994cited by this paper
• Individual dose adaptation of anticancer drugs.

  1994cited by this paper
• Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group.

  1994cited by this paper
• Phase II study with Docetaxel (Taxotere®) in advanced soft tissue sarcomas of the adult

  1994cited by this paper
• Patient characteristics associated with high-risk methotrexate concentrations and toxicity.

  1994cited by this paper

• A minimal physiologically based pharmacokinetic model for high-dose methotrexate

  2021cites this paper
• Targeting pan-essential genes in cancer: challenges and opportunities.

  2020cites this paper
• Doxorubicin area under the curve is an important predictor of neutropenia in dogs with naturally occurring cancers.

  2019cites this paper
• Quantification and clinical application of carboplatin in plasma ultrafiltrate

  2017cites this paper
• Individualizing Dosage Regimens of Antineoplastic Agents

  2017cites this paper
• Anatomical and physiological basis for the allometric scaling of cisplatin clearance in dogs.

  2016cites this paper
• Translational research on influenza virus infection using a nonhuman primate model

  2016cites this paper
• Clinical pharmacy service practice in a Chinese tertiary hospital

  2015cites this paper
• Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA)

  2015cites this paper
• Association of ABCC2 −24C>T Polymorphism with High-Dose Methotrexate Plasma Concentrations and Toxicities in Childhood Acute Lymphoblastic Leukemia

  2014cites this paper
• Influence of genetic polymorphisms of FPGS, GGH, and MTHFR on serum methotrexate levels in Chinese children with acute lymphoblastic leukemia

  2014cites this paper
• The importance of therapeutic drug monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for hematopoietic stem cell transplantation (HSCT) in children.

  2014cites this paper
• Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline

  2014cites this paper
• Exposure–Response Relationships of Anticancer Agents: Application in Drug Development and Drug Label

  2014cites this paper
• Alternative Models in Drug Discovery and Development Part I: In Silico and In Vitro Models

  2014cites this paper
• Development of a limited-sampling model for prediction of doxorubicin exposure in dogs.

  2014cites this paper
• Effects of Adjuvant Chemoradiotherapy on the Frequency and Function of Regulatory T Cells in Patients with Head and Neck Cancer

  2013cites this paper
• The Valley of Death in anticancer drug development: a reassessment.

  2012cites this paper
• Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia

  2012cites this paper
• Optimization of cisplatin doses in a testicular cancer patient with acute renal failure

  2011cites this paper
• Case Studies in Linear and Nonlinear Modeling

  2011cites this paper
• HPLC Method for Monitoring of Degradation Products in Picoplatin Stability Study

  2011cites this paper
• Therapeutic drug monitoring in cancer chemotherapy.

  2010cites this paper
• In vitro chemosensitivity of head and neck cancer cell lines

  2010cites this paper
• Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy.

  2009cites this paper
• Solid-phase extraction of liquiritin and glycyrrhizic acid from licorice using ionic liquid-based silica sorbent.

  2009cites this paper
• Metals in Medicine

  2009cites this paper
• Pharmacological and analytical studies of the cyclin dependent kinase inhibitors

  2009cites this paper
• VEGF G-1154A is Predictive of Severe Acute Toxicities during Chemoradiotherapy for Esophageal Squamous Cell Carcinoma in Japanese Patients

  2008cites this paper
• Dose calculation of anticancer drugs

  2008cites this paper
• Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.

  2008cites this paper
• Pharmacokinetic and pharmacogenetic profiling in solid cancer patients

  2007cites this paper
• Dose-banding of carboplatin: rationale and proposed banding scheme

  2007cites this paper
• Population Pharmacokinetics of the BEACOPP Polychemotherapy Regimen in Hodgkin’s Lymphoma and its Effect on Myelotoxicity

  2007cites this paper
• Chemotherapy dosing part II: alternative approaches and future prospects.

  2007cites this paper
• Chemotherapy dosing part I: scientific basis for current practice and use of body surface area.

  2007cites this paper
• A Systematic Review of Limited Sampling Strategies for Platinum Agents Used in Cancer Chemotherapy

  2007cites this paper
• Genetic Polymorphisms of Drug-Metabolising Enzymes and Drug Transporters in the Chemotherapeutic Treatment of Cancer

  2006cites this paper
• Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.

  2006cites this paper
• The association of chemotherapy induced neutropenia on treatment outcomes in small cell lung cancer.

  2006cites this paper
• Tissue distribution and pharmacodynamics: a complicated relationship.

  2006cites this paper
• Pharmacogenetic screening of docetaxel, irinotecan and fluoropyrimidines in cancer therapy

  2006cites this paper
• Individualised Cancer Chemotherapy: Strategies and Performance of Prospective Studies on Therapeutic Drug Monitoring with Dose Adaptation

  2005cites this paper
• Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.

  2004cites this paper
• Rituximab-Dependent Cytotoxicity by Natural Killer Cells: Influence of FCGR3A Polymorphism on the Concentration-Effect Relationship

  2004cites this paper
• Rituximab-Dependent Cytotoxicity by Natural Killer Cells

  2004cites this paper
• Exposure-Response Relationship of Anticancer Agents

  2004cites this paper
• Pharmacokinetically guided dosing of (high-dose) chemotherapeutic agents

  2004cites this paper
• Protein Binding of Anticancer Drugs

  2004cites this paper
• Mini review Pharmacokinetics of high-dose chemotherapy

  2004cites this paper
• Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.

  2004cites this paper
• Pharmacokinetics of high-dose chemotherapy

  2004cites this paper
• Pharmacokinetic–pharmacodynamic Guided Trial Design in Oncology

  2003cites this paper
• Determination of the platinum drug cis-amminedichloro(2-methylpyridine)platinum(II) in human urine by liquid chromatography-tandem mass spectrometry.

  2003cites this paper
• Pharmacology of Anticancer Drugs in the Elderly Population

  2003cites this paper
• A validated liquid chromatography/tandem mass spectrometry assay for cis-amminedichloro(2-methylpyridine)platinum(II) in human plasma ultrafiltrate.

  2002cites this paper
• Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.

  2002cites this paper
• Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey.

  2002cites this paper
• Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide).

  2002cites this paper
• Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy

  2002cites this paper
• Réflexions pour la mise en place d'un projet global de suivi thérapeutique des anticancéreux

  2002cites this paper
• Analysis of anticancer drugs and their metabolites by mass spectrometry.

  2002cites this paper
• In Vitro pharmacodynamics of CKD-602 in HT-29 cells

  2002cites this paper
• Clinical Pharmacokinetics of Anticancer Drugs:focus on E7070, methotrexate and paclitaxel

  2002cites this paper
• The (ir)relevance of plasma protein binding of anticancer drugs.

  2001cites this paper
• Quantification of busulfan in plasma by liquid chromatography-ion spray mass spectrometry. Application to pharmacokinetic studies in children.

  2001cites this paper
• Sensitive and rapid quantification of busulfan in small plasma volumes by liquid chromatography-electrospray mass spectrometry.

  2001cites this paper